ObesityPhase 3NCT04847557
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
A Phase 3 study testing Tirzepatide in people with Obesity and Heart Failure With Preserved Ejection Fraction (HFpEF), run by Eli Lilly and Company at 146 sites in 10 countries.
Trial summary
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
- What is being tested?
- Tirzepatide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 731 participants
- Where
- 146 sitesin 10 countries
- Study dates
- 20 Apr 2021to 2 Jul 2024
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have a diagnosis of stable heart failure (NYHA class II-IV) and left ventricular ejection fraction (LVEF) ≥50%
- Elevated NT-proBNP (N-terminal pro B-type natriuretic peptide) > 200 picogram/milliliter (pg/ml) for participants without atrial fibrillation (AF), or >600 pg/ml for participants with AF, Structural heart disease (Left atrial enlargement) or Elevated left ventricular filling pressure
- Estimated glomerular filtration rate (eGFR) <70 milliliter (ml)/minute (min)/1.73m² at screening, or HF decompensation within 12 months of screening,
- Stable dose of heart failure medications within 4 weeks of screening
- Body mass index (BMI) ≥30 kilograms per meter squared (kg/m²)
- 6MWD 100-425 meters
- KCCQ CSS ≤80
Who cannot join
- Have had a major cardiovascular event within the last 90 days of screening
- Have had acute decompensated heart failure within 4 weeks of screening
- Have non cardiac causes of functional impairment such as pulmonary arterial hypertension (PAH), severe chronic obstructive pulmonary disease (COPD), anemia, thyroid disease, musculoskeletal disease or orthopedic conditions
- Presence of cardiac amyloidosis, cardiac accumulation disease, cardiomyopathy and severe valvular heart disease
- HbA1c ≥9.5% or uncontrolled diabetes
- History of proliferative diabetic retinopathy or diabetic maculopathy
- Have a history of pancreatitis
- eGFR <15 mL/min/1.73 m² or requiring dialysis at screening
Trial locations and contacts
146 sites in 10 countries.
146 sites in 10 countries
United States54 sites
Lovelace Medical Center
Albuquerque, New Mexico, 87102
Northwest Heart Clinical Research
Arlington Heights, Illinois, 60005
Morehouse School Of Medicine
Atlanta, Georgia, 30310
Maryland Cardiovascular Specialists
Baltimore, Maryland, 21229
McLaren Bay Region
Bay City, Michigan, 48708
DiscoveResearch
Beaumont, Texas, 77701
Westside Medical Associates of Los Angeles
Beverly Hills, California, 90211
Excel Medical Clinical Trials
Boca Raton, Florida, 33434
St. Luke's Boise Medical Center
Boise, Idaho, 83712
Grace Research - Bossier
Bossier City, Louisiana, 71111
Erie County Medical Center
Buffalo, New York, 14215
Capital Area Research, LLC
Camp Hill, Pennsylvania, 17011
Aultman Hospital Research
Canton, Ohio, 44710
Medical University of South Carolina
Charleston, South Carolina, 29425
OnSite Clinical Solutions
Charlotte, North Carolina, 28277
Clearwater Cardiovascular & Interventional Consultants M.D., P.A.
Clearwater, Florida, 33756
Valley Clinical Trials, Inc.
Covina, California, 91723
UT Southwestern Medical Center
Dallas, Texas, 75390
Doylestown Hospital
Doylestown, Pennsylvania, 18901
The Stern Cardiovascular Foundation
Germantown, Tennessee, 38138
Amicis Research Center
Granada Hills, California, 91344
The Heart House
Haddon Heights, New Jersey, 08035
The Heart Clinic - Hammond
Hammond, Louisiana, 70403
Hillsboro Cardiology
Hillsboro, Oregon, 97123
Heart Center Research
Huntsville, Alabama, 35801
Apex Research Foundation
Jackson, Tennessee, 38301
University of California San Diego - La Jolla
La Jolla, California, 92037
Clearwater Cardiovascular & Interventional Consultants M.D., P.A.
Largo, Florida, 33777
Palm Research Center Tenaya
Las Vegas, Nevada, 89128
South Denver Cardiology Associates
Littleton, Colorado, 80120
Rama Research
Marion, Ohio, 43302
North Dallas Research Associates
McKinney, Texas, 75069
Infinite Clinical Research
Miami, Florida, 33133
Cardiovascular Research of Northwest Indiana
Munster, Indiana, 46321
Intermountain Medical Center
Murray, Utah, 84107
Valley Clinical Trials, Inc.
Northridge, California, 91325
Ocala Caridovascular Research
Ocala, Florida, 34471
Hightower Clinical Trial Services
Oklahoma City, Oklahoma, 73102
Midwest Heart & Vascular Specialists
Overland Park, Kansas, 66211
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
UPMC Clinical Trials
Pittsburgh, Pennsylvania, 15213
MultiCare Good Samaritan Hospital
Puyallup, Washington, 98372
Monument Health Rapid City Hospital
Rapid City, South Dakota, 57701
Rochester General Hospital
Rochester, New York, 14621
Clearwater Cardiovascular & Interventional Consultants M.D., P.A.
Safety Harbor, Florida, 34695
East Coast Institute for Research - St. Augustine
Saint Augustine, Florida, 32086
Saratoga Cardiology Associates
Saratoga Springs, New York, 12866
Sherman Clinical Research
Sherman, Texas, 75092
Grace Research - Shreveport
Shreveport, Louisiana, 71105
St. Louis Heart and Vascular, P.C.
St Louis, Missouri, 63136
Cardiology Associates of Fairfield County, P.C.
Stamford, Connecticut, 06905
Stony Brook University
Stony Brook, New York, 11794
Northwest Houston Heart Center
Tomball, Texas, 77375
The Lundquist Institute
Torrance, California, 90502
China21 sites
1st Hospital affiliate to Baotou medical college
Baotou, Inner Mongolia, 014010
Peking University First Hospital
Beijing, Beijing Municipality, 100034
Beijing Friendship Hospital
Beijing, Beijing Municipality, 100050
Jilin Province People's Hospital
Changchun, Jilin, 130021
China-Japan Union Hospital
Changchun, Jilin, 130033
The Third Xiangya Hospital of Central South University
Changsha, Hunan, 410013
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041
The first affiliated hospital of dalian medical university
Dalian, Liaoning, 116000
The First Hospital of Harbin Medical University
Harbin, Heilongjiang, 150001
Jinan Central Hospital
Jinan, Shandong, 250013
Lanzhou university second hospital
Lanzhou, Gansu, 730030
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210000
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210011
Jiangxi Pingxiang People's Hospital
Pingxiang, Jiangxi, 337055
Zhongshan Hospital,Fudan University
Shanghai, Shanghai Municipality, 200032
Huashan Hospital Affiliated Fudan University
Shanghai, Shanghai Municipality, 200040
The People's Hospital of Liaoning Province
Shenyang, Liaoning, 110000
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, 830054
Wuhan University Medical College - Hubei Zhongshan Hospital
Wuhan, Hubei, 430000
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061
Argentina17 sites
Instituto Médico Especializado (IME)
Buenos Aires, Buenos Aires F.D., 1405
Mautalen Salud e Investigación
Buenos Aires, Buenos Aires F.D., C1128AAF
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
Buenos Aires, Buenos Aires F.D., C1425AGC
CIPREC
Buenos Aires, Ciudad Autónoma de Buenos Aire, C1061AAS
CEMEDIC
Buenos Aires, 1407
Fundación Respirar
Buenos Aires, 1426
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autónoma de Buenos Aire, Buenos Air, C1027AAP
Centro de Investigaciones Clinicas Instituto del Corazon (CICIC)
Córdoba, X5002HWE
Instituto de Cardiología "Juana F. Cabral"
Corrientes, 3400
Hospital de Alta Complejidad "Pte. Juan Domingo Perón"
Formosa, 3600
DIM Clínica Privada
Ramos Mejía, Buenos Aires, 1704
Instituto Médico Río Cuarto
Río Cuarto, Córdoba Province, 5800
Instituto de Investigaciones Clinicas Rosario
Rosario, Santa Fe Province, S2000CVD
Centro Cardiovascular Salta
Salta, 4406
Instituto Cardiovascular San Luis
San Luis, 5700
Go Centro Medico San Nicolás
San Nicolás de los Arroyos, Buenos Aires, 2900
Centro de Investigaciones Clinicas del Litoral
Santa Fe, 3000
Brazil11 sites
Centro de Pesquisa Clinica do Coracao
Aracaju, Sergipe, 49055-530
Hospital Angelina Caron
Campina Grande do Sul, Paraná, 83430-000
Centro de Pesquisa Sao Lucas
Campinas, São Paulo, 13034-685
Instituto de Pesquisa clinica de Campinas
Campinas, São Paulo, 13060-080
Loema Instituto de Pesquisa Clinica
Campinas, São Paulo, 13092133
Universidade Federal de Goias
Goiânia, Goiás, 74605-020
CAPED Centro Avancado Pesquisa e Diagnostica
Ribeirão Preto, São Paulo, 14026-900
IBPClin - Instituto Brasil de Pesquisa Clínica
Rio de Janeiro, 22241-180
Pesquisare Saude
Santo André, São Paulo, 09080-110
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, São Paulo, 15090000
CEPIC - Centro Paulista de Investigação Clínica
São Paulo, 04266-010
Israel11 sites
Barzilai Medical Center
Ashkelon, Southern District, 7830604
Hillel Yaffe Medical Center
Hadera, Northern District, 3810101
Rambam Health Care Campus
Haifa, Northern District, 3109601
Shaare Zedek Medical Center
Jerusalem, Jerusalem, 9013102
Hadassah Medical Center
Jerusalem, Jerusalem, 9112001
Meir Medical Center
Kfar Saba, Central District, 4428164
Galilee Medical Center
Nahariya, Northern District, 2210001
Rabin Medical Center
Petah Tikva, Central District
Sheba Medical Center
Ramat Gan, Central District, 5262100
Kaplan Medical Center
Rehovot, Central District, 7610001
Sourasky Medical Center
Tel Aviv, Tell Abīb, 6423906
India10 sites
CIMS Hospital - Care Institute of Medical Sciences
Ahmedabad, Gujarat, 380060
Narayana Institute of Cardiac Sciences
Bangalore, Karnataka, 560099
Medanta The Medicity
Gurugramam, Haryana, 122018
AIG Hospitals
Hyderabad, Telangana, 500032
King Edward Memorial Hospital & Seth Gordhandas Sunderdas Medical College
Mumbai, Maharashtra, 400012
Government Medical College And Hospital - Nagpur
Nagpur, Maharashtra, 440009
Central India Cardiology and Research Institute
Nagpur, Maharashtra, 440015
Vijan Hospital & Research Centre
Nashik, Maharashtra, 422005
G.B. Pant Institute of Postgraduate Medical Education & Research
New Delhi, National Capital Territory of Delhi, 110002
Batra Hospital and Medical Research Centre
New Delhi, National Capital Territory of Delhi, 110062
Mexico7 sites
Fundación Cardiovascular de Aguascalientes A.C.
Aguascalientes, 20230
Hospital Cardiologica Aguescalientes
Aguascalientes, 20230
Virgen Cardiovascular Research SC
Guadalajara, Jalisco, 44670
Cardiolink Clin Trials
Monterrey, Nuevo León, 64060
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, 66460
Centro de Estudios Clínicos de Querétaro (CECLIQ)
Querétaro, 76000
CIMAB SA de CV
Torreón, Coahuila, 27000
Taiwan7 sites
Mackay Memorial Hospital-Hsinchu
Hsinchu, 300
Kaohsiung Medical University Hospital
Kaohsiung City
Chung Shan Medical University Hospital
Taichung, Taichung, 402
National Taiwan University Hospital
Taipei, 10002
Taipei Medical University Hospital
Taipei, 110
Taipei Veterans General Hospital
Taipei, 11217
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, 333
Russia6 sites
Ivanovo Regional Healthcare Institution Cardiology Dispensary
Ivanovo, Ivanovo Oblast, 153012
Izhevsk City Clinical Hospital Number 9
Izhevsk, Udmurtiya Republic, 426063
Russian Cardiology Research and Production Complex
Moscow, Moscow, 121552
Russian Medical Academy of Postgraduate Education
Moscow, Moscow, 125993
Ryazan Regional Clinical Cardiological Dispensary
Ryazan, Ryazan Oblast, 390026
Astarta Clinic
Saint Petersburg, Sankt-Peterburg, 199226
Puerto Rico2 sites
Clinical Research Center - Universidad Central del Caribe (CRC - UCC)
Bayamón, 00956
Research and Cardiovascular Corp.
Ponce, 00717
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
Read the detailed description
The study will continue until approximately 52 weeks after the last participant is randomized. The maximum duration of an individual's participation is estimated to be ~120 weeks and will depend on duration of study enrollment.
- Being tested
- Tirzepatide, Placebo
- Keywords
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TirzepatideDrug
Also called LY3298176
Administered SC
PlaceboOther
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| Tirzepatide | Experimental | Participants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or maximum tolerated dose (MTD) tolerated by the participant (5 mg QW or 10 mg QW). Receives: Drug: Tirzepatide |
| Placebo | Placebo comparator | Participants received placebo administered SC QW. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
The KCCQ is a 23-item, participant self-administered questionnaire that assesses impacts of heart failure "over the past 2 weeks" on the following 7 domains:
- Physical Limitation (6)
- Symptom Stability (1)
- Symptom Frequency (4)
- Symptom Burden (3)
- Self-Efficacy (2)
- Quality of Life (3)
- Social Limitation (4)
Each of the 23 individual items are answered on Likert scales of varying lengths (5, 6, or 7-point scales).
KCCQ-CSS includes the symptom and physical limitation domains of the KCCQ. Scores are obtained by averaging the associated individual items and transforming the score to a 0 to 100 range. Higher scores indicate better health status.
Least Square (LS) mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (<35, >=35 kg/m2) + Treatment (Type III sum of squares) as variables .
Measured: Baseline, Week 52
First Occurrence of the Composite Endpoint of Heart Failure (HF) Outcomes
Clinical Endpoint Committe confirmed Occurrences of CV outcomes were reported here. HF outcomes consisted of cardiovascular death and HF events.
The HF events were defined as worsening clinical symptoms or signs related to HF, which are meaningful to the participant and require intensification of treatment characterized by 1 or more of the following:
- hospitalization for heart failure regardless of duration or treatment received
- use of intravenous drug, usually an intravenous diuretic, but may include intravenous vasodilators or positive inotropic drugs, or
- augmentation or increase in oral diuretic therapy.
Measured: Baseline Up To 160 weeks
Secondary outcomes (9)
Change From Baseline in Exercise Capacity as Measured by 6-Minute Walk Distance (6MWD)
Participants performed an exercise capacity assessment using the 6-Minute Walk Test (6MWT) and the distance covered (6MWD) was assessed in meters. The 6MWT was performed indoors on a straight, flat, hard surface that is at least 30 meters in length. The greater distance walked meant better physical capacity.
LS Mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (<35, >=35 kg/m2) + Treatment (Type III sum of squares) as variables.
Measured: Baseline, Week 52
Percent Change From Baseline in Body Weight
Percent change in bodyweight was reported. LS mean was determined using ANCOVA model with Baseline + HF Decompensation Within 12 Months of Screening + T2DM Status + Baseline BMI group (<35, >=35 kg/m2) + Treatment (Type III sum of squares) as variables.
Measured: Baseline, Week 52
Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Percent change from baseline in hsCRP was reported. LS Mean was determined using ANCOVA model with log (actual measurement/baseline) = log (baseline) + HF decompensation within 12 months of screening + T2DM status + baseline BMI group (<35, >=35 kg/m2) + Treatment (Type III sum of squares) as variables.
Measured: Baseline, Week 52
Win Percentage of the Hierarchical Composite Endpoint
Hierarchical Composite Endpoint included time to all-cause death, number of HF events, time to first HF events, KCCQ-CSS, 6MWD.
The winner was determined in each pair-wise comparison in the following order:
- A delayed first occurrence of all-cause death
- If the pair cannot be differentiated based on death, winner has fewer HF events
- If the pair cannot be differentiated by number of HF events, winner has delayed time to occurrence of first HF event
- If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in 6MWD
- If the pair still cannot be differentiated, winner has a more favorable category for change from baseline in KCCQ-CSS
- Otherwise the pair will be recorded as tied.
Reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.
Measured: Baseline Up To 160 Weeks
Percentage of Participants With New York Heart Association (NYHA) Class Change
Percentage of participants with NYHA class change at Week 52 was reported.
Measured: Week 52
Number of Participants With Time to All-Cause Death
All-cause mortality is death due to any cause. Number of participants with time to all-cause mortality are presented.
Measured: Baseline Up To 160 Weeks
Number of Participants With Time to First Occurrence of HF Events
Number of participants with time to first occurrence of HF events are reported.
Measured: Baseline Up To 160 Weeks
Number of HF Events and All-Cause Death
Number of HF events and all-cause death are reported.
Measured: Baseline Up To 160 Weeks.
Number of Recurrent HF Events
Number of recurrent HF events were reported.
Measured: Baseline Up To 160 Weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2021
- Study start20 Apr 2021
- Primary completion2 Jul 2024
- Study completion2 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 731 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04847557
- Sponsor's protocol ID
- 17757
- Other IDs
- I8F-MC-GPID
- Status last verified
- Aug 2025
- First submitted
- 26 Feb 2021
- Last updated
- 20 Aug 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Borlaug BA, Zile MR, Kramer CM, Litwin SE, Ye W, Ou Y, Hurt K, Murakami M, Packer M; SUMMIT Trial Group. Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial. JACC Heart Fail. 2026 Jul 7:103218. doi: 10.1016/j.jchf.2026.103218. Online ahead of print.
PubMed 42417681Packer M, Zile MR, Kramer CM, DiMaria JM, Baum SJ, Litwin SE, Murakami M, Zhou C, Ou Y, Koeneman L, Borlaug BA; SUMMIT Trial Study Group. Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. J Am Coll Cardiol. 2025 Sep 9;86(10):696-707. doi: 10.1016/j.jacc.2025.06.058.
PubMed 40903131Borlaug BA, Zile MR, Kramer CM, Ye W, Ou Y, Hurt K, Murakami M, Packer M; SUMMIT Trial Study Group. Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial. J Am Coll Cardiol. 2025 Jul 29;86(4):242-255. doi: 10.1016/j.jacc.2025.04.059.
PubMed 40701669Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA; SUMMIT Trial Study Group. Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial. J Am Coll Cardiol. 2025 May 13;85(18):1721-1735. doi: 10.1016/j.jacc.2025.03.009. Epub 2025 Mar 31.
PubMed 40162940Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M; SUMMIT Trial Study Group. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol. 2025 Feb 25;85(7):699-706. doi: 10.1016/j.jacc.2024.11.001. Epub 2024 Nov 18.
PubMed 39566869Zile MR, Borlaug BA, Kramer CM, Baum SJ, Litwin SE, Menon V, Ou Y, Weerakkody GJ, Hurt KC, Kanu C, Murakami M, Packer M; SUMMIT Trial Study Group. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation. 2025 Mar 11;151(10):656-668. doi: 10.1161/CIRCULATIONAHA.124.072679. Epub 2024 Nov 18.
PubMed 39556714Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC, Murakami M, Borlaug BA; SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025 Jan 30;392(5):427-437. doi: 10.1056/NEJMoa2410027. Epub 2024 Nov 16.
PubMed 39555826Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, Murakami M, Ou Y, Upadhyay N, Packer M. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med. 2025 Feb;31(2):544-551. doi: 10.1038/s41591-024-03374-z. Epub 2024 Nov 17.
PubMed 39551891Reese-Petersen AL, Holm Nielsen S, Bulow Sand JM, Schattenberg JM, Bugianesi E, Karsdal MA. The sclerotic component of metabolic syndrome: Fibroblast activities may be the central common denominator driving organ function loss and death. Diabetes Obes Metab. 2024 Jul;26(7):2554-2566. doi: 10.1111/dom.15615. Epub 2024 May 3.
PubMed 38699780